Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
16.91
+3.38 (24.98%)
At close: Aug 13, 2025, 4:00 PM
16.56
-0.35 (-2.07%)
Pre-market: Aug 14, 2025, 9:25 AM EDT
Stoke Therapeutics Employees
Stoke Therapeutics had 128 employees as of December 31, 2024. The number of employees increased by 18 or 16.36% compared to the previous year.
Employees
128
Change (1Y)
18
Growth (1Y)
16.36%
Revenue / Employee
$1,561,664
Profits / Employee
$410,039
Market Cap
923.23M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
STOK News
- 1 day ago - Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 3 days ago - Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome - Business Wire
- 7 days ago - Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates - Business Wire
- 7 days ago - Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference - Business Wire
- 4 weeks ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress - GlobeNewsWire
- 5 weeks ago - Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress - Business Wire
- 2 months ago - Stoke Therapeutics: Impressive Pipeline And Big Backers - Seeking Alpha